Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences

Tóth, Erika and Kürönya, Zsófia and Soós, Edina and Pintér, Tamás and Butz, Henriett and Horváth, Zsolt and Csernák, Erzsébet and Grolmusz, Vince Kornél and Székely, Judit and Straussz, Tamás and Lövey, József and Jánvári, Levenete and Báthory-Fülöp, László and Nagy, Péter and Polgár, Csaba and Patócs, Attila (2024) Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences. Acta Oncologica, 63. pp. 433-440. ISSN 0284-186X

Preview

Text AO39918.pdf - Published Version Available under License Creative Commons Attribution. Download (908kB) | Preview

Abstract

Recent developments in molecular genetic testing methods (e.g. next-generation sequencing [NGS]panels) largely accelerated the process of finding the most appropriate targeted therapeutic intervention for cancer patients based on molecularly targetable genetic alterations. In Hungary, a centralized approval system following the recommendation of the National Molecular Tumor Board was launched for the coordination of all aspects of comprehensive genetic profiling (CGP) including patient selection and therapy reimbursement. Aim: The study aims to evaluate the clinical benefit of CGP in our Comprehensive Cancer Center Methods and patients: CGP was introduced into our routine clinical practice in 2021. An NGS-based large (> 500 genes) gene panel was used for cases where molecular genetic testing was approved by the National Molecular Tumor Board. From 2021 until August 2023 163 cases were tested. The majority of them were ECOG 0–1 patients with advanced-stage diseases, histologically rare cancer, or cancers with unknown primary tumours. Results: Seventy-four cases (74 of 163, 45%) had clinically relevant genetic alterations. In 34 patients, the identified variants represented an indication for an approved therapy (approved by the Hungarian authorities, on-label indication), while in 40 cases the recommended therapy did not have an approved indication in Hungary for certain tumour types, but off-label indication could be recommended. Based on our CGP results, 24 patients (24/163; 14.7%) received targeted therapy. Treatment duration was between 1 and 60 months. In total 14 (14/163; 8.5% of the tested cases) patients had a positive clinical response (objective response or stable disease) and were treated for more than 16 weeks. Interpretation: NGS-based CGP was successfully introduced in our institution and a significant number of patients benefited from comprehensive genetic tests. Our preliminary results can serve as the starting point of Drug Rediscovery Protocol (DRUP) studies.

Actions (login required)

Edit Item